A single-center pilot prospective randomly assigned compared with a dummy treatment neither you nor the study doctors know who gets the real treatment clinical trial. Study objective - to investigate the how well it works and safety of levosimendan in patients in the perioperative period following pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension (CTEPH).
Official registry: https://clinicaltrials.gov/study/NCT07914933 · Meshalkin Research Institute of Pathology of Circulation · enrollment listed as 50
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
If you join, the listed intervention(s) are Infusion of levosimendan, or Placebo infusion "Soluvit". The registry lists allocation as randomized. A single-center pilot prospective randomly assigned compared with a dummy treatment neither you nor the study doctors know who gets the real treatment clinical trial.
They plan to enroll about 50 people at Novosibirsk. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
The Effect of Levosimendan on Pulmonary Artery Pressure and Right Ventricular Function in the Perioperative Period in Patients With CTEPH After Pulmonary Thromboendarterectomy: a Single-center Pilot Prospective Randomized Placebo-controlled Double-blind Clinical Trial
Interventions: Infusion of levosimendan, Placebo infusion "Soluvit"
Primary outcome (registry wording): Mean pulmonary artery pressure (mPAP)
Gleb Moroz, PhD
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
This study is not a treatment protocol and no experimental treatments are involved. Study participants may be seen as needed for clinical, translational and basic research studies, or as medically indicated.
NCT00081523 · Official ClinicalTrials.gov record · National Heart, Lung, and Blood Institute (NHLBI)
Background: \- High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. Some people have disease-associated PAH and some have PAH from an unknown cause.
NCT01730092 · Official ClinicalTrials.gov record · National Institutes of Health Clinical Center (CC)
Background: \- Noncirrhotic Portal Hypertension (NCPH) is caused by liver diseases that increase pressure in the blood vessels of the liver. It seems to start slowly and not have many warning signs.
NCT02417740 · Official ClinicalTrials.gov record · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary